reports
- Oscar Haffen Lamm
CALLIDITAS: Cautious guidance leaves room for surprise as Tarpeyo ente...
Yesterday, Calliditas reported its Q4 Tarpeyo sales reaching SEK 347.3m (USD 32.6m), with total net sales at SEK 1.206bn for FY 2023, in line with the USD 100-120m guidance, and a cash position at SEK 973.7m. All in all, the Q4 performance was solid, while the main surprise came with the conservati
- Healthcare Team
- Alex Cogut
- Ingird Gafanhão
Reports Q1 2023 results, sees sales uptake by the end of the quarter
Q1 2023 Tarpeyo sales reached SEK 186m (USD 17m), representing a modest 11% increase vs. the previous quarter. The ambitious FY 2023 net sales guidance for Tarpeyo of USD 120-150m was reiterated, as the company expects sales to further grow in the coming quarters considering that i) Q1 enrollment w
- Healthcare Team
- Alex Cogut
- Ingird Gafanhão
- Olga Smolentseva
Phase 3 meets eGFR primary endpoint and suggests best-case scenario
The phase 3 NefIgArd trial with Nefecon (Tarpeyo/Kinpeygo) met the primary endpoint of a two-year benefit on eGFR vs. placebo. We expect to see more details in the call later today, but Calliditas already stated that the benefit was observed irrespective of UPCR (proteinuria) at baseline. We believ
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.